David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.

Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.

Miguel Regueiro, MD, offers his clinical advice on second-line therapies for patients with Crohn’s Disease (CD).

Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.

Experts summarize their clinical strategies for monitoring and treating patients with Crohn’s Disease (CD).

Anita Afzali, MD, discusses treatment approaches to ulcerative colitis (UC) and how they may differ from Crohn’s Disease (CD).

Miguel Regueiro, MD, discusses the role of ozanimod as a treatment option for ulcerative colitis (UC).

Millie Long, David Hudesman, MD, Maia Kayal, MD, and Miguel Regueiro, MD, discuss treatment strategies for ulcerative colitis (UC) utilizing ustekinumab.

Experts discuss how they utilize Janus kinase (JAK) inhibitors for patients with ulcerative colitis (UC).

Experts offer clinical advice on therapy sequencing of Janus kinase (JAK) inhibitors for ulcerative colitis (UC) and when surgery may be appropriate.

Experts discuss the recent use of biosimilars like inolimomab as treatment for ulcerative colitis (UC).

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.